Efficiency of lenalidomide, bortezomib and prednisone (RVP) in patients with newly diagnosed multiple myeloma

Efficiency of lenalidomide, bortezomib and prednisone (RVP) in patients with newly diagnosed multiple myeloma

Objective: to study the efficacy and safety of the antitumor RVP program (lenalidomide, bortezomib, prednisone) as a first-line therapy in patients with multiple myeloma (MM). Materials and methods. A prospective study involved 39 patients with MM (15 women, 24 men), median age 61 years (30–76 years...

Full description

Bibliographic Details
Main Authors:	K. A. Belousov, T. A. Mitina, Yu. Yu. Chuksina, A. K. Golenkov, E. V. Kataeva, E. V. Trifonova, Yu. B. Chernykh, L. L. Vysotskaya, S. G. Zakharov, E. F. Klinushkina, A. N. Mitin
Format:	Article
Language:	Russian
Published:	ABV-press 2019-04-01
Series:	Онкогематология
Subjects:	multiple myeloma first-line therapy lenalidomide bortezomib polichemotherapy
Online Access:	https://oncohematology.abvpress.ru/ongm/article/view/331

Similar Items

Efficacy of lenalidomide, bortezomib, and prednisolone in patients with relapsed or refractory multiple myeloma
by: T. A. Мitinа, et al.
Published: (2015-12-01)

Bortezomib, lenalidomide, and dexamethasone versus bortezomib, doxorubicin, and dexamethasone in newly diagnosed multiple myeloma
by: Dong Liang, et al.
Published: (2024-09-01)

Myxoma Virus Combination Therapy Enhances Lenalidomide and Bortezomib Treatments for Multiple Myeloma
by: Alpay Yeşilaltay, et al.
Published: (2024-01-01)

PHA RMA COE CONOMI CAL EVALUATION OF MULTIPLE MYELOMA TREATMENT WITH REVLIMID (LENALIDOMIDE ) IN THE RUSSIAN FEDE RATION
by: R. Yagudina, et al.
Published: (2015-03-01)

Evaluating the difference in clinical efficacy for t(11;14) multiple myeloma patients with CD20- or CD20+
by: ZHAO Weihong, HUANG Bintao, LIU Rui, XIANG Caixia
Published: (2023-09-01)

PHARMACOECONOMIC EVALUATION OF POMALIDOMIDE (IMNOVID) FOR THE TREATMENT OF RECURRENT AND REFRACTORY MULTIPLE MYELOMA
by: M. Yu. Frolov, et al.
Published: (2017-08-01)

Bortezomib (velcade) plus melphalan and prednisone in elderly untreated patients with multiple myeloma
by: S. S. Bessmeltsev, et al.
Published: (2022-11-01)

Pomalidomide in relapsed and refractory multiple myeloma: multicenter retrospective study
by: V. G. Potapenko, et al.
Published: (2022-07-01)

Alectinib combined with VRCD and BV monoclonal antibody for the treatment of ALK-positive large B-cell lymphoma: a case report and literature review
by: Hongxia Wang, et al.
Published: (2025-01-01)

The multicenter experience with bendamustine in the treatment of relapsed and refractory multiple myeloma
by: S. V. Voloshin, et al.
Published: (2015-10-01)

Ixazomib combined with lenalidomide and dexamethasone chemotherapy for newly diagnosed multiple myeloma in China—Compared with bortezomib/lenalidomide/dexamethasone
by: Zhongjun Huo, et al.
Published: (2023-02-01)

Current status and updated recommendations for diagnosis and treatment of plasma cell myeloma in Switzerland
by: Panagiotis Samaras, et al.
Published: (2015-02-01)

Integrating novel agents into multiple myeloma treatment – current status in Switzerland and treatment recommendations
by: C Taverna, et al.
Published: (2010-09-01)

Single agent lenalidomide activity in multiple myeloma relapse evidenced uniquely by CT/PET
by: Alessandro Gozzetti, et al.
Published: (2014-08-01)

Bortezomib, Lenalidomide and Dexamethasone Combination Induced Complete Remission in Relapsed/Refractory Plasmablastic Lymphoma: Case Report of a Potential Novel Treatment Approach
by: Waleed Sabry, et al.
Published: (2022-07-01)

Real-world outcomes of maintenance therapy post-autologous stem cell transplantation in newly diagnosed multiple myeloma
by: Ka-Won Kang, et al.
Published: (2025-02-01)

Integrating novel agents into multiple myeloma treatment – current status in Switzerland and treatment recommendations
by: Swiss Medical Weekly
Published: (2010-04-01)

Effective response with bortezomib retreatment in relapsed multiple myeloma
by: Christian Taverna, et al.
Published: (2012-04-01)

Incidence, characteristics, and treatments of peripheral neuropathy in multiple myeloma patients receiving bortezomib (velcade)
by: S. S. Bessmeltsev, et al.
Published: (2022-11-01)

Single agent lenalidomide activity in multiple myeloma relapse evidenced uniquely by CT/PET
by: Alessandro Gozzetti, et al.
Published: (2012-01-01)

Single agent lenalidomide activity in multiple myeloma relapse evidenced uniquely by CT/PET
by: Alessandro Gozzetti, et al.
Published: (2012-06-01)

Bortezomib neurotoxicity treatment of multiple myeloma: single center experience and literature review
by: N. V. Stepanova, et al.
Published: (2022-11-01)

Cutaneous Drug Reaction Due to Bortezomib Characterized by Erythematous Reticular Plaques in a Patient With Multiple Myeloma
by: Emre Güven, et al.
Published: (2024-10-01)

A real‐world retrospective–prospective analysis of efficacy and safety of combined ixazomib, lenalidomide, and dexamethasone in relapsed/refractory multiple myeloma: The northern Italy experience
by: Anna Furlan, et al.
Published: (2024-04-01)

LENALIDOMIDE IN COMBINATION WITH DEXAMETHASONE IN ELDERLY PATIENTS WITH ADVANCED, RELAPSED OR REFRACTORY MULTIPLE MYELOMA AND RENAL FAILURE
by: Patrizia Tosi
Published: (2013-06-01)

Comparison of Time to Next Treatment or Death Between Front‐Line Daratumumab, Lenalidomide, and Dexamethasone (DRd) Versus Bortezomib, Lenalidomide, and Dexamethasone (VRd) Among Transplant‐Ineligible Patients With Multiple Myeloma
by: Doris K. Hansen, et al.
Published: (2024-11-01)

Long-term continuous treatment as a new strategy for relapsed or refractory multiple myeloma
by: S. V. Semochkin
Published: (2020-07-01)

Case report: A patient with ALK-positive large B-cell lymphoma benefited from myeloma-like treatment combined with the ALK inhibitor lorlatinib
by: Dan Liu, et al.
Published: (2024-03-01)

Chemoresistance of PRAME-expressing melanoma cell can be resolved with help of bortezomib
by: V. A. Misyurin, et al.
Published: (2019-01-01)

Lenalidomide for relapsed or refractory multiple myeloma
by: S. S. Bessmeltsev1, et al.
Published: (2014-07-01)

Periorbital necrobiotic xanthogranuloma resolved with three years of systemic lenalidomide treatment
by: Llwyatt K. Hofer, et al.
Published: (2025-03-01)

Proteasome inhibitor bortezomib prevents proliferation and migration of pulmonary arterial smooth muscle cells
by: Yi‐Ching Liu, et al.
Published: (2024-06-01)

Bortezomib a safety treatment for patients with Multiple Myeloma and Cystic Fibrosis
by: Fabiana Gentilini, et al.
Published: (2012-01-01)

Bortezomib a safety treatment for patients with Multiple Myeloma and Cystic Fibrosis
by: Fabiana Gentilini, et al.
Published: (2012-05-01)

LENALIDOMIDE RETREATMENT IN A PATIENT WITH RELAPSED MULTIPLE MYELOMA WHO HAD PREVIOUSLY RESPONDED TO LENALIDOMIDE
by: Vincenzo Federico
Published: (2014-08-01)

Results of multiple myeloma treatment with bortezomib
by: T. I. Pospelova, et al.
Published: (2022-11-01)

Ixazomib or Lenalidomide combined with cyclophosphamide and dexamethasone in the treatment of elderly transplant-ineligible newly diagnosed multiple myeloma
by: Yan Wang, et al.
Published: (2025-02-01)

Stem cell collection after lenalidomide, bortezomib and dexamethasone plus elotuzumab or isatuximab in newly diagnosed multiple myeloma patients: a single centre experience from the GMMG-HD6 and -HD7 trials
by: Joseph Kauer, et al.
Published: (2023-11-01)

ID221 Bortezomib for the treatment of Multiple Myeloma: A Systematic Review and Meta-Analysis
by: Vania dos Santos Nunes Nogueira, et al.
Published: (2024-11-01)

Cost-Effectiveness of Rituximab Versus Bortezomib in Kidney Transplant Patients
by: Yadgar Rashidi, et al.
Published: (2024-05-01)